Monotherapy studies have also shown that bemcentinib is well tolerated and has disease-modulating effects in acute myeloid leukemia (AML) and triple-negative breast cancer (TNBC), especially in tumors exhibiting epithelial–mesenchymal transition (EMT) phenotypes driven by Axl. Here, AXL is linked to acute myeloid leukemia.